Immunogenicity screening in protein drug development. (Q49168236)

18 February 2018

title

Immunogenicity screening in protein drug development. (English)

1 reference

18 February 2018

author

Paul Whi Parren

3

1 reference

18 February 2018

author name string

Ivo Van Walle

1

1 reference

18 February 2018

Yannick Gansemans

2

1 reference

18 February 2018

Philippe Stas

4

1 reference

18 February 2018

Ignace Lasters

5

1 reference

18 February 2018

language of work or name

English

0 references

publication date

1 March 2007

1 reference

18 February 2018

Expert Opinion on Biological Therapy

published in

1 reference

18 February 2018

volume

7

1 reference

18 February 2018

issue

3

1 reference

18 February 2018

page(s)

405-418

1 reference

18 February 2018

Detection of IGA anti-OKT3 antibodies in OKT3-treated transplant recipients

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Abciximab readministration: results of the ReoPro Readministration Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Review article: safety of infliximab in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Preoperative clinical radioimmunodetection of pancreatic cancer by 111 In-labeled chimeric monoclonal antibody Nd2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Natalizumab for active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Antigen presentation by MHC class II molecules: invariant chain function, protein trafficking, and the molecular basis of diverse determinant capture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

T-cell antigen receptor genes and T-cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Positive and negative selection of T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Receptor clustering and transmembrane signaling in T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Combination of HLA-A and HLA class II alleles controls the susceptibility to rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Celiac disease: caught between a rock and a hard place

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

The genetics of HLA-associated disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Association of HLA-DR and -DQ genes with narcolepsy in Koreans: comparison with two control groups, randomly selected subjects and DRB1*1501-DQB1*0602--positive subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Sequence analysis of peptides bound to MHC class II molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A novel strategy for the discovery of MHC class II-restricted tumor antigens: identification of a melanotransferrin helper T-cell epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Rationally engineered therapeutic proteins with reduced immunogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Staphylokinase-specific cell-mediated immunity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

An in vitro human cell-based assay to rank the relative immunogenicity of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

T-cell epitope mapping using the ELISPOT approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

CD4+ T cell epitope identification: applications to allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Activation markers of peripheral blood mononuclear cells in late pregnancy and after delivery: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Binding interactions between peptides and proteins of the class II major histocompatibility complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

SYFPEITHI: database for MHC ligands and peptide motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Specific and general HLA-DR binding motifs: comparison of algorithms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

ProPred: prediction of HLA-DR binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Two complementary methods for predicting peptides binding major histocompatibility complex molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Application of an artificial neural network to predict specific class I MHC binding peptide sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Predicting peptides that bind to MHC molecules using supervised learning of hidden Markov models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Application of support vector machines for T-cell epitopes prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Relating amino acid sequence to phenotype: analysis of peptide-binding data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Fast and accurate side-chain topology and energy refinement (FASTER) as a new method for protein structure optimization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

A novel predictive technique for the MHC class II peptide-binding interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Quantitative structure-activity relationships and the prediction of MHC supermotifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Ab initio prediction of peptide-MHC binding geometry for diverse class I MHC allotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

DynaPred: a structure and sequence based method for the prediction of MHC class I binding peptide sequences and conformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Learning MHC I--peptide binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Human population-based identification of CD4+ T-cell peptide epitope determinants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.3.405

21 January 2018

Identifiers

DOI

10.1517/14712598.7.3.405

1 reference

18 February 2018

1 reference

18 February 2018